• 1.

    Wheeler DC, et al. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. Nephrol Dial Transplant. Published online August 30, 2020. doi: 10.1093/ndt/gfaa234AstraZeneca

    • Search Google Scholar
    • Export Citation
  • 2.

    Farxiga Phase III DAPA-CKD trial will be stopped early after overwhelming efficacy in patients with chronic kidney disease. March 30, 2020. https://www.astrazeneca.com/media-centre/press-releases/2020/farxiga-phase-iii-dapa-ckd-trial-will-be-stopped-early-after-overwhelming-efficacy-in-patients-with-chronic-kidney-disease.html

    • Search Google Scholar
    • Export Citation
  • 3.

    Packer M, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. New Engl J Med. Published online August 29, 2020. doi: 10.1056/NEJMoa2022190

    • Search Google Scholar
    • Export Citation
  • 4.

    McMurray J, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019; 381:19952008. doi: 10.1056/NEJMoa1911303

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 5.

    Perkovic V, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019; 380:22952306. doi: 10.1056/NEJMoa1811744

SGLT2s Show Promise for Kidney Protection Benefits Seen in Patients with and without Diabetes

Restricted access
Save